Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Bilusic on the Non-ccRCC Treatment Armamentarium

March 29th 2024

Marijo Bilusic, MD, PhD, discusses combination regimens under investigation for patients with non–clear cell renal cell carcinoma.

Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC

March 29th 2024

Focusing on belzutifan, Laurence Albigès, MD, PhD, reviews data from the LITESPARK-005 clinical trial, and Martin H. Voss, MD, discusses the ongoing LITESPARK-011 trial.

CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC

March 29th 2024

Experts on advanced RCC discuss the CONTACT-03 trial evaluating atezolizumab plus cabozantinib following immune checkpoint inhibitor treatment in patients with inoperable disease.

Dr Merchán on the Role of Immunotherapy and TKI Combinations in RCC

March 28th 2024

Jaime R. Merchán, MD, discusses the current roles for immunotherapy and TKIs in patients with renal cell carcinoma.

Dr Xu on Ongoing Research Initiatives in ccRCC

March 27th 2024

Wenxin (Vincent) Xu, MD, highlights research in renal cell carcinoma, spotlighting developments and updates in patients with non-clear cell disease.

Dr Xu on Changes in Systemic Therapy in RCC

March 26th 2024

Wenxin (Vincent) Xu, MD, on evolving systemic therapy and the utilization of biomarkers in the treatment of renal cell carcinoma.

Exciting New Approaches in Metastatic Urothelial Carcinoma

March 25th 2024

Experts on bladder cancer discuss exciting new agents and treatment strategies and where they can potentially fit into urothelial cancer treatment paradigms.

Treatment Sequencing Practices in Metastatic Urothelial Carcinoma

March 25th 2024

Focusing on metastatic urothelial carcinoma, the panel discusses the role of chemotherapy and outlines treatment sequencing approaches.

Dr Xu on Treatment Decision-Making in RCC

March 22nd 2024

Wenxin (Vincent) Xu, MD, discusses treatment decision-making in patients with renal cell carcinoma.

Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC

March 22nd 2024

David A. Braun, MD, PhD, provides clinical insights on factors that influence treatment decisions in the second line and beyond for patients with advanced clear cell RCC.

LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research

March 22nd 2024

Focusing on the LITESPARK-003 and LITESPARK-024 trials, Laurence Albigès, MD, PhD, discusses novel doublet regimens under investigation in the first-line setting in advanced renal cell carcinoma.

Later-Line Therapies for Metastatic Urothelial Carcinoma

March 18th 2024

Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.

Cisplatin Eligibility and Maintenance Therapy in Metastatic Urothelial Carcinoma

March 18th 2024

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

Dr Liu on Surgical Outcomes Following Radiation and Chemotherapy in Rectal Cancer

March 16th 2024

I-Chia (Daniel) Liu, MD, discusses surgical and local control outcomes following short-course radiation therapy and chemotherapy for rectal cancer.

Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC

March 15th 2024

Medical oncologists provide clinical insights on managing adverse events associated with IO-TKI and IO-IO regimens in patients with advanced renal cell carcinoma.

CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC

March 15th 2024

The expert panel reacts to 55-month follow-up data from CheckMate 9ER assessing nivolumab plus cabozantinib in patients with newly diagnosed advanced RCC.

Retrospective Study Shows Neoadjuvant SCRT is Associated With Optimal Surgical Outcomes in Rectal Cancer

March 14th 2024

Prolonged duration from neoadjuvant SCRT to surgery did not increase the risk of poor mesorectum specimen quality or post-operative morbidity in rectal cancer.

Dr Rini on the FDA Approval of Belzutifan in Relapsed/Refractory RCC

March 13th 2024

Brian I. Rini, MD, FASCO, shares the importance of the FDA approval of belzutifan in patients with advanced renal cell carcinoma.

Clinical Insights on Recent Data in Metastatic Urothelial Carcinoma

March 11th 2024

GU medical oncologists offer their impressions of recent updates in the metastatic urothelial carcinoma space, focusing on CheckMate 901 and EV-302.

Emerging Data in Metastatic Urothelial Carcinoma

March 11th 2024

Neeraj Agarwal, MD, FASCO, provides a comprehensive overview of recent data in metastatic urothelial carcinoma, highlighting the CheckMate 901 and EV-302 studies.